The instruction for medical use
of Aldiviya Torgovoye medicine
Mezhdunarodnoye’s name the unlicensed name
Is not present
the Dosage form
of the Capsule of 7.5 mg
One capsule contains
active agent – bifenildimetildikarboksilat 7.5 mg,
excipients: polyethyleneglycol 400, glycerin, povidone
the Structure of a cover
of the Gelatin capsule, glycerin concentrated D-sorbitol solution, methylparahydroxybenzoate, the titan dioxide (E171), ethylvanillin, dye yellow No. 5 aluminum varnish, the water purified.
Soft capsules of an oval form of orange color with colourless or pale orange contents
Drugs for treatment of diseases of a liver and biliary tract. Drugs for treatment of diseases of a liver
the ATX A05BA Code
Bifinildimetildikarboksilat (BDD) is badly soluble in water. At oral administration of tablets, the bioavailability bifinildimetildikarboksilat is 20-30%. The soft capsule of Aldiviya, contains the BDD soluble form which is quicker soaked up in an organism in comparison with other solid dosage forms. The peak of concentration is defined in blood plasma in 1.5 hours. Does not kumulirut in an organism.
is Quickly distributed in body tissues. The highest concentrations are established in lungs, a liver and kidneys and in insignificant quantities in tissues of a brain and a spleen.
Metabolism of BDD happens in a liver to formation of 5 metabolites (CYP1A2, CYP2C9 and CYP3A4 of isoenzymes of P450 cytochrome) by O-demethylation of group of carboxymethylcellulose and demethylation of metilendioksifenilny group.
About 70% is allocated from an organism with bile within 48 hours, generally in the form of metabolites. Very small amount of drug is removed with urine.
Drug for treatment of diseases of a liver. Bifenildimetildikarboksilat – a synthetic analog of a skhizandrin With, one of the components received from fruits of a magnolia vine Chinese.
At injury of a liver of various genesis there is an increase in development of free radicals which is followed by damage of mitochondrions of hepatocytes and death of cells of a liver.
BDD make favorable impact on the damaged liver cells, preventing peroxide oxidation of lipids and increasing activity of antioxidant enzymes. Drug reduces the level of alaninaminotranspherase (ALT), making the inhibiting impact on the CCl4-induced peroxide oxidation of lipids and on linking of CCl-4 of metabolites with lipids of microsomes of a liver.
Aldiviya raises possibilities of a liver to a detoxication and reduces mutagenicity of chemical carcinogens, such as aflatoxin In and benzapiren. Protects a liver from the damages induced by chemical toxins, such as CCl4 (phenoxin) and acetothioamide, medicines, viruses.
After administration of drug the improvement of function of a liver due to strengthening of processes of a detoxication, decrease in pathological damages and acceleration of regeneration of hepatocytes is noted.
Increase in detoksikatsionny ability of drug happens due to increase in P450 level and increase in activity of CYP450. Drug induces P450 expression, increases activity glutathione peroxidases, glutationreduktaza and glutathiones-S-transferases that leads to a giperoksidation of lipids in hepatocytes, an inactivation of toxic substances in a liver and to prevention of destruction of cellular structures.
Clinical action of Aldiviya is shown in improvement of the general condition of patients and decrease in symptoms of dysfunction of a liver (such as weakness, heavy feeling in right hypochondrium, loss of appetite, dyspepsia, swelling and an abdominal pain). Laboratory indicators improve: decrease of the activity of transaminases, decrease in level gamma glutamiltransferazy and globulin, increase in seralbumin.
as a part of complex therapy in the following diseases:
– chronic hepatitis
– toxic damages of a liver (alcoholism, intoxication compounds of heavy metals, medicinal damages of a liver)
Applies the Route of administration and doses inside, after a meal.
The adult on 1 – 2 capsules at one time 3 times a day. Maximum single dose 2 capsules. Maximum daily dose of 6 capsules.
At return of the ALT level to a normal indicator accept on 1 capsule 2 times a day. Duration of therapy is from 1 to 6 months. Duration of treatment is defined by the attending physician.
Patients of advanced age
At patients of advanced age the daily dose is defined individually. Use of drug it is necessary to begin with 1 capsule 2-3 times a day.
Use for patients with a renal failure
of Researches at patients with a renal failure was not carried out, in this regard it is recommended to be careful at use of drug for such patients.
– a dieback
– tranzitorny jaundice
– hypersensitivity to any component of drug
– children’s and teenage age up to 18 years
– pregnancy and the period of a lactation
– an acute hepatitis and cirrhosis.
Joint reception with inosine can lead medicinal interactions to repeated increase in the ALT level. At a concomitant use of Aldiviya with other medicines the cases of incompatibility are not known.
instructions Use in pediatrics
In view of lack of experience of use for children, children should not appoint Aldiviya up to 18 years.
At several patients the increase in the ALT level was noted during treatment. The ALT level could increase at the therapy termination, but also could return to normal with treatment resuming.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
does not affect ability to run the vehicle or other potentially dangerous mechanisms.
is not revealed. In case of overdose – symptomatic treatment.
The form of release and packing
On 10 capsules place in blister strip packagings from a film of polyvinylchloride and aluminum foil.
On 6 planimetric packs together with the instruction for medical use in the state and Russian languages place in a cardboard pack.
To Store storage conditions at a temperature not above 25ºС.
To store out of children’s reach!
A period of storage
not to use drug after the expiry date specified on packing.
According to the prescription